Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in autosomal dominant polycystic kidney disease (ADPKD)
2009-010920-24Phase 4Active
- Sponsor
- FIBHULP
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by FIBHULP. Primary endpoints: Change in renal volume at 12 months, Change in hepatic volume at 12 months and 1 more. Started Mar 2009; status: active.
02
Drugs
sirolimus
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2009-010920-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010920-24.